|
**Overview**: Spino-Bulbar Muscular Atrophy Panel**Introduction**: The Spino-Bulbar Muscular Atrophy Panel is a diagnostic tool designed to screen for SBMA using whole blood samples. In India, SBMA (Kennedy's disease) is an X-linked trinucleotide repeat disorder (CAG expansion in AR gene, typically >38 repeats), presenting in males with progressive bulbar and limb weakness, gynecomastia, and androgen insensitivity (prevalence ~1 in 30,000-40,000 males, underreported in rural areas). High morbidity from underdiagnosis in rural/low-SES men with slowly progressive muscle wasting, cramps, tremor, or infertility, limited genetic labs, delayed supportive care leading to respiratory failure, falls, or misdiagnosis as ALS. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs PCR for AR gene CAG repeats, mutation status, and genetic profile over 1-2 days with high accuracy, valuable for confirming diagnosis and repeat sizing (correlates with severity/onset). This diagnostic falls under genetic screening and targets adult males with motor neuron signs + androgen features or family history, addressing accurate detection to guide physical therapy, androgen monitoring, and family counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise molecular confirmation and reducing disability burden in affected families. Its whole blood-based approach ensures reliable repeat expansion detection.**Other Names**: SBMA Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: AR CAG expansion identified 1991; in India, reported in neurology cohorts.**Purpose**: The test assesses 3 parameters including AR Gene CAG Repeats to guide SBMA screening, confirm expansion, inform prognosis/counseling.**Test Parameters**: 1. AR Gene CAG Repeats, 2. Mutation Status, 3. Genetic Profile.**Pretest Condition**: No fasting required; patients should have progressive weakness or gynecomastia.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on weakness onset, family history, androgen symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed SBMA including progression, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and size repeats within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Expanded CAG repeats (>38) confirm SBMA, necessitating specialist input.**Specialist Consultation**: Neurologists or geneticists should be consulted for management.**Additional Supporting Tests**: EMG, androgen levels, muscle biopsy for confirmation.**Test Limitations**: Repeat size interpretation complex; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Neuromuscular Studies India 2023. |
